Active, not recruiting
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- Research Site Birmingham, Alabama, United States
- Research Site Mobile, Alabama, United States
- Research Site Yuma, Arizona, United States
- Research Site Glendale, California, United States